Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine augmentation therapy in treatment-resistant depression
DRKS00000021Phase 3Recruiting
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olanzapine in major depressive disorder (MDD), treatment-resistant depression (TRD), sponsored by Universitätsklinikum Freiburg. Started Sep 2008; status: recruiting.
02
Drugs
olanzapine
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on DRKS00000021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000021.